Proactive Investors - Run By Investors For Investors

Summit Therapeutics to present successful studies of ridinilazole at IDWeek

Summit Therapeutics is on track to begin Phase III clinical trials of ridinilazole in the first quarter of next year
IDWeek started on Wednesday and runs until Sunday

Summit Therapeutics PLC (LON:SUMM) plans to present recent successful studies of its ridinilazole treatment for C. difficile infection (CDI) at the infectious disease conference IDWeek 2018 in San Francisco.

The company, which is on track to begin Phase III clinical trials of ridinilazole in the first quarter of next year, will present previous studies showing that the precision antibiotic can target C. Diff bacteria without also damaging the natural gut flora and that it is better than the current gold standard, vancomycin.

READ: Ridinilazole leading the way as Summit Therapeutics pivots to antibiotics

Dr David Roblin, president of R&D of Summit, said the primary endpoint of the Phase II trial will measure how ridinilazole can treat CDI and reduce recurrent CDI.

“If the phase III clinical trial results are positive, we believe these measures would differentiate ridinilazole in CDI and support its front-line use,” he said.

IDWeek started on Wednesday and runs until Sunday.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
August 22 2018
The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.
September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use